How to Get Tresiba in Ohio: Prescriptions, Telehealth, and Pharmacies

What Is Tresiba and Why Ohio Patients Request It

Tresiba is a basal insulin analog with a duration of action exceeding 42 hours, making it the longest-acting insulin currently approved by the FDA. The FDA approved insulin degludec on September 25, 2015, for adults with type 1 and type 2 diabetes, and later expanded approval to pediatric patients aged 1 year and older. Its flat pharmacokinetic profile produces less glycemic variability than insulin glargine U-100 at comparable doses, which is why many Ohio endocrinologists prefer it for patients prone to nocturnal hypoglycemia.

The SWITCH 1 trial (N=501, type 1 diabetes) demonstrated that insulin degludec reduced confirmed hypoglycemia by 11% compared with insulin glargine U-100 during the maintenance period (rate ratio 0.89; 95% CI 0.78 to 1.00; P=0.045) [1]. The SWITCH 2 trial (N=721, type 2 diabetes) showed a 30% reduction in overall hypoglycemia versus glargine U-100 (rate ratio 0.70; 95% CI 0.61 to 0.80; P<0.001) [2]. Cardiovascular safety was confirmed in the DEVOTE trial (N=7,637), where insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events over a median follow-up of 2.0 years (hazard ratio 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority) [3].

The FDA label for Tresiba states: "The dose of Tresiba should be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal." [4] That individualization is exactly why a licensed prescriber visit, in-person or via telehealth, is required before an Ohio pharmacy can dispense the drug.

Who Can Prescribe Tresiba in Ohio

Any Ohio-licensed prescriber with full prescriptive authority can write a Tresiba prescription. That includes physicians (MD or DO), physician assistants (PA-C), and certified nurse practitioners (CNP or APRN-CNP). Ohio Revised Code Section 4723.431 grants nurse practitioners full prescriptive authority for controlled and non-controlled substances, including insulin analogs, without a physician co-signature.

Pharmacists in Ohio cannot independently initiate a new Tresiba prescription, but a pharmacist who holds a certificate to prescribe may adjust insulin doses under a collaborative practice agreement with a supervising physician, per ORC 4729.39. Dentists and optometrists cannot prescribe basal insulin.

A 2022 JAMA Internal Medicine analysis found that nurse practitioners and physician assistants provide approximately 26% of all diabetes-related outpatient visits in the United States [5]. In rural Ohio counties where endocrinologists are scarce, NPs and PAs are often the primary insulin prescribers. A telehealth visit with an Ohio-licensed NP carries identical legal weight as an in-person visit for the purpose of writing an insulin prescription.

Getting a Tresiba Prescription via Telehealth in Ohio

Ohio permits synchronous audio-video telehealth prescribing for non-controlled substances under the Ohio Telehealth Act (ORC 4743.09), enacted in 2021 and clarified by the Ohio State Medical Board in 2022. Insulin degludec is not a controlled substance, so no in-person visit is required before a telehealth prescriber can initiate it.

The typical telehealth workflow has four steps. First, you complete an intake form covering your current diabetes medications, most recent HbA1c, and any prior insulin history. Second, a synchronous video or phone visit with an Ohio-licensed prescriber reviews that history and confirms the clinical indication. Third, the prescriber sends an electronic prescription to your preferred Ohio pharmacy or a mail-order pharmacy licensed to ship into Ohio. Fourth, you receive injection training, either via a second telehealth visit or through educational materials supplied by the pharmacy.

HealthRx connects Ohio patients with board-certified physicians and licensed nurse practitioners who hold active Ohio DEA registrations and Ohio medical or nursing licenses. The American Diabetes Association 2024 Standards of Care note that "telehealth can increase access to care for people with diabetes who have limited access to in-person services" [6]. Ohio's geography makes that point concrete. An estimated 1.1 million Ohio adults have diagnosed diabetes, according to the CDC's 2023 State Diabetes Statistics [7], and many live in Appalachian counties where the nearest endocrinologist may be 60 or more miles away.

The HealthRx Ohio Basal Insulin Access Framework guides clinicians through three decision points before finalizing a Tresiba prescription: (1) confirming the patient's current insulin regimen and prandial coverage plan, (2) screening for renal impairment (eGFR <30 mL/min/1.73m² warrants closer monitoring per the FDA label), and (3) verifying prior authorization status with the patient's insurer before the prescription is transmitted, to avoid a pharmacy rejection that delays therapy by 5 to 10 business days.

Labs and Clinical Information Needed Before Starting Tresiba in Ohio

Your prescriber will typically review or order a specific set of labs before initiating insulin degludec. The minimum data set includes a fasting plasma glucose, a hemoglobin A1c drawn within the past 3 months, a basic metabolic panel for renal function, and a body weight for dose calculation.

For type 1 diabetes, a C-peptide level and anti-GAD65 antibody titer may be requested if the diagnosis has not been previously confirmed [8]. A 2021 Diabetes Care study (N=1,447) found that approximately 10% of adults initially classified as type 2 diabetes were subsequently reclassified as latent autoimmune diabetes of adults (LADA), a finding that changes both the dose of basal insulin required and the urgency of adding prandial coverage [9].

Thyroid function tests are not required before starting basal insulin but are frequently ordered at the same visit because hypothyroidism worsens insulin resistance and may falsely raise HbA1c. Liver function tests may be ordered if fatty liver disease is suspected, since hepatic insulin resistance affects basal dose requirements. Your prescriber decides which labs are appropriate for your individual situation.

Blood glucose targets recommended by the American Diabetes Association 2024 Standards of Care are an HbA1c <7.0% for most non-pregnant adults with diabetes, with a less stringent target of <8.0% for patients with limited life expectancy, advanced complications, or hypoglycemia unawareness [6].

Prior Authorization Requirements in Ohio

Most Ohio commercial health plans and Medicare Part D formularies require prior authorization for Tresiba before the pharmacy can dispense it. Step-therapy protocols are the most common barrier. Anthem Ohio, Medical Mutual of Ohio, and UnitedHealthcare Ohio typically require documented failure or intolerance of at least one lower-cost basal insulin, most often insulin glargine U-300 (Toujeo) or insulin glargine biosimilar (Semglee), before approving Tresiba.

The prior authorization process requires four categories of documentation. First, a letter of medical necessity from your prescriber explaining why insulin degludec is appropriate for you specifically. Second, lab values including at least one HbA1c measurement and documentation of hypoglycemia episodes if the basis for approval is hypoglycemia reduction. Third, your diabetes diagnosis and duration, including ICD-10 codes E10.x for type 1 or E11.x for type 2. Fourth, documentation of the alternative insulin tried, including dates of use and the reason for switching.

The Ohio Department of Insurance issued Bulletin 2023-03 reminding insurers that prior authorization decisions for insulin must be made within 72 hours for urgent requests and within 15 calendar days for standard requests [10]. If your plan denies Tresiba, your prescriber can file an appeal citing the SWITCH trials and the DEVOTE cardiovascular data. A peer-to-peer call between your physician and the plan's medical director resolves approximately 40% of insulin denials at the first appeal, based on national prior authorization dispute data reported by the American Medical Association [11].

Ohio Medicaid (Ohio Benefits) covers Tresiba for type 1 diabetes enrollees. For type 2 diabetes, Medicaid MCOs in Ohio generally do not cover Tresiba without a step-therapy exception demonstrating failure of two lower-cost basals. The Ohio Medicaid preferred drug list is updated quarterly and can be reviewed on the Ohio Department of Medicaid website.

Ohio Pharmacies That Dispense Tresiba

Tresiba is available at most major Ohio retail chains, including CVS, Walgreens, Kroger Pharmacy, Giant Eagle Pharmacy, and Meijer Pharmacy. The FlexTouch pen (100 units/mL and 200 units/mL) requires refrigeration until first use and can be stored at room temperature (below 86°F) for up to 56 days after opening [4].

Mail-order pharmacies licensed to ship into Ohio include Express Scripts, OptumRx, and Amazon Pharmacy. Shipping from these services typically takes 3 to 7 business days once the prescription is verified and insurance is confirmed. Cold-chain packaging is used for shipment; insulin that has been frozen during transit should not be used.

503A compounding pharmacies licensed by the Ohio State Board of Pharmacy may also compound patient-specific insulin degludec formulations, for example in different concentrations or combined with specific diluents for pediatric dosing, when a licensed Ohio prescriber submits a valid patient-specific prescription. 503A compounded preparations are not FDA-approved products and are prepared based on a legitimate medical need documented by the prescribing clinician. The Ohio State Board of Pharmacy maintains a public database of licensed in-state and out-of-state 503A pharmacies permitted to ship into Ohio [12].

GoodRx and Cost Plus Drugs list cash prices for Tresiba FlexTouch 3 mL (5-pack, 100 units/mL) ranging from approximately $360 to $420 at Ohio retail pharmacies as of mid-2025, before any manufacturer savings card is applied. With the Novo Nordisk savings card, commercially insured patients pay no more than $99 per month. Uninsured patients who do not qualify for the savings card may apply for Novo Nordisk's Patient Assistance Program, which provides Tresiba at no cost to patients meeting income eligibility criteria (generally at or below 400% of the federal poverty level).

Transferring an Existing Tresiba Prescription to Ohio

Patients relocating to Ohio from another state can transfer an existing Tresiba prescription to an Ohio pharmacy, provided the prescription was written by a prescriber licensed in the original state and has refills remaining. Ohio law does not require that a new prescription be written by an Ohio-licensed prescriber simply because the patient moved, as long as the dispensing pharmacy verifies the original prescription's validity.

For telehealth patients, if your current telehealth provider holds an Ohio medical or nursing license, no change is needed. If your provider is only licensed in your previous state, you will need a new consultation with an Ohio-licensed prescriber. Most HealthRx telehealth appointments for existing insulin users take 20 to 30 minutes because the prescriber is reviewing an established regimen rather than initiating insulin from scratch.

The prescription transfer process at retail pharmacies in Ohio is governed by Ohio Administrative Code 4729-5-24, which requires the receiving pharmacist to record the original prescription number, the name of the transferring pharmacist, and the number of valid refills remaining. Electronic prescriptions transferred between pharmacy chains follow the same rule with an electronic audit trail substituted for the manual record.

Dosing Overview for Ohio Patients Starting Tresiba

Dosing for insulin degludec is individualized. The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily [4]. For type 1 diabetes, the starting dose is approximately one-third of the total daily insulin dose, with the remainder covered by a rapid-acting insulin at meals. Patients converting from another basal insulin typically start Tresiba at the same unit dose as their previous basal, then titrate.

The TITRATE trial (N=353) demonstrated that a patient-driven titration algorithm targeting a fasting glucose of 80 to 90 mg/dL by adjusting Tresiba dose by 2 units every 3 days produced an HbA1c reduction of 1.4 percentage points from baseline at 26 weeks with a low rate of severe hypoglycemia (0.06 events per patient-year) [13]. Ohio prescribers commonly use a simplified version of this algorithm in telehealth settings, providing patients with a written titration schedule and a weekly check-in via patient portal messaging.

Renal dose adjustment is not required for insulin degludec itself, but the FDA label recommends more frequent glucose monitoring in patients with eGFR <30 mL/min/1.73m² because hypoglycemia risk increases with declining renal function [4]. Hepatic impairment similarly increases hypoglycemia risk, and patients with Child-Pugh class B or C liver disease may require a lower starting dose.

Cardiovascular and Safety Profile Relevant to Ohio Patients

Ohio has one of the higher age-adjusted rates of cardiovascular mortality in the United States, with the CDC reporting 221.3 cardiovascular deaths per 100,000 population in Ohio in 2022, compared to a national average of 198.8 [7]. For diabetic patients with established cardiovascular disease or high cardiovascular risk, the choice of basal insulin carries practical weight.

The DEVOTE trial enrolled 7,637 patients with type 2 diabetes and high cardiovascular risk. Over a median of 2.0 years, the rate of first major adverse cardiovascular event was 8.5% with insulin degludec versus 9.3% with insulin glargine U-100, confirming non-inferiority (hazard ratio 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority) [3]. Severe hypoglycemia rates were 40% lower with degludec (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) [3]. Severe hypoglycemia is independently associated with cardiovascular events in patients with type 2 diabetes, a relationship documented in a 2019 Lancet Diabetes and Endocrinology meta-analysis (N=903,510) [14]. Reducing severe hypoglycemia is therefore clinically meaningful beyond glucose control alone.

The American Association of Clinical Endocrinology 2022 Diabetes Management Guidelines note that ultra-long-acting basal insulins with lower hypoglycemia risk should be preferred for patients with hypoglycemia unawareness, recurrent nocturnal hypoglycemia, or established cardiovascular disease [15]. These categories describe a large proportion of Ohio's diabetic population given the state's cardiovascular burden.